Factor Model (net +1.4)
Factor Model
net +1.4 4.0 / 10NMRA-511 Phase 1b clears agitation endpoint, heads to higher doses
Watch: Higher dose testing results in late 2026 or early 2027 will determine whether agitation reduction scales and whether the safety window remains intact. Timing and interim data releases matter — any safety signals or efficacy plateau derail the narrative fast.
Neumora Therapeutics presented Phase 1b data for NMRA-511, its Alzheimer's agitation treatment, at the Guggenheim Biotech Summit on February 11, 2026. The study met its primary effect size endpoints with favorable safety and tolerability, clearing the path for higher dose testing later this year. Leerink Partners initiated coverage on January 12 with an Outperform rating and $8 price target.
Early-stage biotech advances hinge on de-risking molecule safety before broader efficacy testing. NMRA-511 passing Phase 1b without major safety flags keeps the program on track — this is table stakes, not a victory lap. The real inflection comes if higher dose cohorts show dose-dependent efficacy signals without safety degradation.
Evidence
Fundamentals & Data ▾
Recent transactions
Get alerted when NMRA changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.